Trevena to Present at the Stifel 2019 Healthcare Conference

CHESTERBROOK, Pa., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer, will present at the Stifel 2019 Healthcare Conference, sponsored by Stifel, to be held at the Lotte New York Palace Hotel in New York City on Wednesday, November 20, 2019 at 8:35 a.m. EST.

A live audio webcast and archived replay of the presentation will be available on Trevena’s investor relations website at https://investors.trevena.com/. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.

For more information about the conferences, or to schedule a one-on-one meeting with Trevena’s management, please contact KCSA Strategic Communications at [email protected], or send an email to [email protected] (Stifel).

About Trevena
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has four novel and differentiated investigational drug candidates, including IV oliceridine, for the management of moderate-to-severe acute pain in hospitals, TRV250 for the acute treatment of migraine, and TRV734 for maintenance treatment of opioid use disorder. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to managing chronic pain.

For more information, please contact:

Investor Contact:
Valter Pinto / Allison Soss
KCSA Strategic Communications
Phone: 212-896-1254 / 212-896-1267
Email: [email protected]  

Company Contact:
Bob Yoder, SVP and Chief Business Officer
Trevena, Inc.
Phone: 610-354-8840